Veramarx careers

Veramarx offers the only accurate diagnostic test for early-stage Lyme disease, which is one of the fastest growing infectious disease in the US and Western Europe. Lyme disease can only be treated effectively when diagnosed at the early stage of infection, when 75% of patients visit the doctor. Current tests are highly inaccurate, missing over 60% of the cases in the early stage. The company has two patents pending.

Traditional blood test with a proprietary interpretive algorithm that detects a signature of immune response biomarkers that indicate the presence of Lyme disease infection

Status: completed initial validation study; product ready for launch via CLIA laboratory at National Jewish Health

92% sensitivity, and 99% negative predictive value (rule out test)
$2.5B in annual savings US, according to a Johns Hopkins’ independent health economics study
93% of doctors would order the Veramarx test, per an independent survey of ordering physicians